Skip to main content

DoubleTwist Licenses Database to Merck

NEW YORK, Nov 29 – DoubleTwist has licensed its annotated human genome database package to Merck, DoubleTwist announced Wednesday.

The two-year license agreement covers the database and software for visualizing and interpreting the gene information, which Merck and seven affiliated companies plan to use in drug discovery. Merck had previously used DoubleTwist’s bioinformatics software.

“We are pleased to expand our existing relationship with a leading pharmaceutical company such as Merck," DoubleTwist CEO John Couch said in a statement." Prophecy provides a secure way for Merck to rapidly access and integrate our regularly updated annotated data within its in-house software systems."

The parties did not disclose additional terms of the agreement.

DoubleTwist’s other pharmaceutical customers for its bioinformatics software have included Eli Lilly, Isis Pharmaceuticals, and Bristol Myers Squibb. But Merck is the first major pharmaceutical company to publicly sign on for DoubleTwist’s new database.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.